Parathyroid hormone-related protein is an essential growth factor for human clear cell renal carcinoma and a target for the von Hippel-Lindau tumor suppressor gene

T Massfelder, H Lang, E Schordan, V Lindner… - Cancer Research, 2004 - AACR
T Massfelder, H Lang, E Schordan, V Lindner, S Rothhut, S Welsch, P Simon-Assmann…
Cancer Research, 2004AACR
Clear cell renal carcinoma (CCRC) is responsible for 2% of cancer-related deaths
worldwide and is resistant to virtually all therapies, indicating the importance of a search for
new therapeutic targets. Parathyroid hormone-related protein (PTHrP) is a polyprotein
derived from normal and malignant cells that regulates cell growth. In the current study, we
show that blocking PTHrP with antibodies or antagonizing the common parathyroid hormone
(PTH)/PTHrP receptor, the PTH1 receptor, dramatically blunts the expansion of human …
Abstract
Clear cell renal carcinoma (CCRC) is responsible for 2% of cancer-related deaths worldwide and is resistant to virtually all therapies, indicating the importance of a search for new therapeutic targets. Parathyroid hormone-related protein (PTHrP) is a polyprotein derived from normal and malignant cells that regulates cell growth. In the current study, we show that blocking PTHrP with antibodies or antagonizing the common parathyroid hormone (PTH)/PTHrP receptor, the PTH1 receptor, dramatically blunts the expansion of human CCRC in vitro by promoting cell death. Importantly, in nude mice, anti-PTHrP antibodies induced complete regression of 70% of the implanted tumors by inducing cell death. In addition, we demonstrate that the von Hippel-Lindau tumor suppressor protein, which functions as a gatekeeper for CCRC, negatively regulates PTHrP expression at the post-transcriptional level. These studies indicate that PTHrP is an essential growth factor for CCRC and is a novel target for the von Hippel-Lindau tumor suppressor protein. Taken together, these results strongly suggest that targeting the PTHrP/PTH1 receptor system may provide a new avenue for the treatment of this aggressive cancer in humans.
AACR